ResearcherUniversity of Central FloridaNo recent work listed

David Paladino

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5066659814. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper

Papers 2

A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. Co-author DOI 10.18632/oncotarget.6635 ↗
A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0019605 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

James Turkson · 2 shared papers, 2011–2016 · strength 0.10
- Paper A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. DOI 10.18632/oncotarget.6635 ↗
- Paper A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. DOI 10.1371/journal.pone.0019605 ↗
Jared David Acoba · 1 shared paper, 2016 · strength 0.07
- Paper A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. DOI 10.18632/oncotarget.6635 ↗
Soumya Jaganathan · 1 shared paper, 2011 · strength 0.03
- Paper A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. DOI 10.1371/journal.pone.0019605 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.